Effect of symbiotic administration on selected health indices in a human volunteer trial (dietary intervention)

Submission date	Recruitment status	Prospectively registered
16/06/2006	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
07/07/2006	Completed	Results
Last Edited	Condition category	Individual participant data
25/09/2009	Nutritional, Metabolic, Endocrine	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Marika Mikelsaar

Contact details

Ravila 19 Tartu Estonia 50411 +372 (0)7 374 179 marika.mikelsaar@ut.ee

Additional identifiers

Protocol serial number 96/94

Study information

Scientific Title

Study objectives

The consumption of probiotic and prebiotic agents' influence on the human gastrointestinal ecosystem that may manifest the possible shifts in health indices in response to symbiotic intake.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved by the Ethics Review Committee on Human Research of the University of Tartu on 21 /08/2001, reference number: 96/94

Study design

Randomised double-blind dietary (symbiotic) cross-over intervention study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Healthy adults

Interventions

Symbiotic consumption versus placebo capsule. Volunteers were randomly allocated to receive either:

- 1. One sachet of prebiotic (6.6 g Raftilose®; P95) and two capsules of the freeze-dried probiotics (Lactobacillus fermentum ME-3, Lactobacillus paracasei 8700:2, Bifidobacterium longum 46; 3 x 10^9 colony forming units [CFU]) per day
- 2. Placebo (maltodextrin) twice a day for three weeks

After a two-week washout period, volunteers were crossed over to another three weeks of symbiotic or placebo administration.

Details of Joint Sponsor: Estonian Science Foundation Sihtasutus Eesti Teadusfond Endla 4, Tallinn Estonia http://www.etf.ee/

Intervention Type

Other

Phase

Not Specified

Primary outcome(s)

The primary outcome measure is to assess the effect of symbiotic intake on health indices, biochemical markers, and faecal microflora

Key secondary outcome(s))

- 1. To assess the health indices of healthy adults (body mass index, blood pressure, bone mineral density)
- 2. The self-reported questionnaire was applied containing questions on welfare, nutritional habits, and habitual gastrointestinal symptoms (abdominal pain, flatulence, bloating, and stool frequency)
- 3. All subjects completed a modified semi-quantitative questionnaire about their nutritional habits
- 4. To determine haematological indices (haemoglobin, white blood cell count, red blood cells, platelets), plasma glucose, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL), high-density lipoprotein-cholesterol (HDL), triglyceride and high-sensitive C-reactive protein (hsCRP) levels
- 5. To determine total antioxidative activity (TAA), total antioxidative status (TAS), oxidized low density lipoprotein (oxLDL), baseline diene conjugates of LDL (BDC-LDL) in blood samples
- 6. To determine in urine the content of 8-isoprostanes and biogenic amines
 7. Faecal samples were analysed for presence of Helicobacter pylori antigen by the Helicobacter pylori stool antigen (HpSA) test (ImmunoCard STAT HpSA, Meridian Bioscience Europe, Italy)
 9. Fluorescence in situ hybridisation (FISH) was used to monitor changes in faecal microflora
- after consumption of synbiotic

Completion date

30/06/2005

Eligibility

Key inclusion criteria

- 1. Wish to participate in the study
- 2. Aged 20-60 years
- 3. Healthy (i.e. no known health problems and no medical conditions that require drug therapy)
- 4. Signed informed consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Αll

Key exclusion criteria

- 1. History of any gastrointestinal disease
- 2. Use of any antimicrobial drug within last month
- 3. Use of any regular concomitant medication, including medical preparations
- 4. Pregnancy or breastfeeding
- 5. Food allergy

Date of first enrolment

17/02/2005

Date of final enrolment 30/06/2005

Locations

Countries of recruitment

Estonia

Study participating centre Ravila 19

Tartu Estonia 50411

Sponsor information

Organisation

EU Commission (Belgium)

ROR

https://ror.org/00k4n6c32

Funder(s)

Funder type

Government

Funder Name

EU Commission

Funder Name

Estonian Science Foundation (Estonia)

Alternative Name(s)

Estonian Science Foundation, ETF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

Estonia

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration